Analysis of the Factors That Affect the Detection Duration of SARS-CoV-2 in Loop Mediated Isothermal Amplification among COVID-19 Inpatients-Reference-Cited by-同舟云学术

Analysis of the Factors That Affect the Detection Duration of SARS-CoV-2 in Loop Mediated Isothermal Amplification among COVID-19 Inpatients

Published:2023-09-30 Issue:5 Volume:76 Page:282-288
ISSN:1344-6304
Container-title:Japanese Journal of Infectious Diseases
language:en
Short-container-title:Jpn J Infect Dis

Author:

Maruyama Kohei¹,Sekiya Kiyoshi¹,Yanagida Noriyuki²,Nakayama Kanae³,Kushida Yusuke¹,Yasuda Shuhei¹,Fukumoto Daisuke¹,Hosoya Satoshi⁴,Moriya Hiromitsu⁵,Katsumi Manabu⁶

Affiliation:

1. Department of Infection Control and Prevention, National Hospital Organization Sagamihara National Hospital, Japan

2. Department of Pediatrics, National Hospital Organization Sagamihara National Hospital, Japan

3. Department of Clinical Laboratory, National Hospital Organization Sagamihara National Hospital, Japan

4. Department of Emergency and Critical Care Medicine, National Hospital Organization Sagamihara National Hospital, Japan

5. Department of Surgery, National Hospital Organization Sagamihara National Hospital, Japan

6. Department of Pharmacy, National Hospital Organization Sagamihara National Hospital, Japan

Publisher

Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

https://www.jstage.jst.go.jp/article/yoken/76/5/76_JJID.2023.095/_pdf

Reference40 articles.

1. 1. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327:639-651.

2. 2. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection—increasing community access to testing program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1526-1530.

3. 3. Terada M, Ohtsu H, Saito S, et al. Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open. 2021;11:e047007.

4. 4. Fontana LM, Villamagna AH, Sikka MK, et al. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): review of current literature. Infect Control Hosp Epidemiol. 2021;42:659-668.

5. 5. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021;3:CD013705.